CompletedNot Applicable

LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care

United States53 participantsStarted 2021-09-14

Plain-language summary

Investigators will develop and pilot test a culturally tailored, trauma-informed smartphone app, called LinkPositively, for Black WLHA affected by interpersonal violence. The goal is to determine preliminary effects of the intervention on HIV care (i.e., retention in HIV care, ART adherence) and mental health outcomes (e.g., PTSD, depression, anxiety). Through a randomized control trial (RCT), participants will be randomly assigned to either the intervention arm (n=40) or control arm (Ryan White standard of care, n=40), with follow-up at 3- and 6- months. This study will benefit the advancement of HIV prevention science by harnessing technology to promote engagement in HIV care, while improving social support through peers and social networking-all under the auspices of being trauma-informed for Black WLHA with experiences of interpersonal violence.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female Gender * Black or African-American racial/ethnic background * Aged 18 years or older * HIV-positive status * Ever experienced physical, sexual, and/or psychological abuse by a current or former partner or non-partner (e.g., relative, friend, stranger) * Owner of a smartphone with internet browsing capabilities * English speaking Exclusion Criteria: * Male Gender * Aged 17 or younger * HIV-negative status

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of HIV Care Visits

Timeframe: 3 Months Post-Baseline

Number of HIV Care Visits

Timeframe: 6 Months Post-Baseline

Number of Participants With ART Adherence

Timeframe: 3 Months Post-Baseline

Number of Participants With ART Adherence

Timeframe: 6 Months Post-Baseline

HIV Adherence Self-Efficacy

Timeframe: 3 Months Post-Baseline

HIV Adherence Self-Efficacy

Timeframe: 6 Months Post-Baseline

Trial details

NCT IDNCT04199052

SponsorUniversity of California, San Diego

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-31

Results submitted2025-05-15

View on ClinicalTrials.gov More HIV/AIDS trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of HIV Care Visits

Timeframe: 3 Months Post-Baseline

Number of HIV Care Visits

Timeframe: 6 Months Post-Baseline

Number of Participants With ART Adherence

Timeframe: 3 Months Post-Baseline

Number of Participants With ART Adherence

Timeframe: 6 Months Post-Baseline

HIV Adherence Self-Efficacy

Timeframe: 3 Months Post-Baseline

HIV Adherence Self-Efficacy

Timeframe: 6 Months Post-Baseline